Grillo Perez Santiago, Diaz-Brochero Candida, Garzon Herazo Javier Ricardo, Muñoz Velandia Oscar Mauricio
Department of Internal Medicine, Hospital Universitario San Ignacio, Carrera 7 No 40-62, 7th Floor, Bogotá 110231, Colombia.
School of medicine, Pontifical Xavierian University, Carrera 7 No 40-62, 8th Floor, Bogotá 110231, Colombia.
Ther Adv Infect Dis. 2024 Mar 11;11:20499361241237615. doi: 10.1177/20499361241237615. eCollection 2024 Jan-Dec.
Uncomplicated bacteremia remains a leading cause of morbidity and mortality in hospitalized patients. Current guidelines recommend a minimum of 14 days of treatment.
To evaluate the efficacy and safety of short usual antibiotic therapy in adults with uncomplicated . bacteremia (SAB).
We developed a search strategy to identify systematic review and meta-analysis of non-randomized studies (NRS), comparing short usual or long antibiotic regimens for uncomplicated SAB in MEDLINE, Embase, and the Cochrane Register up to June 2023. The risk of bias was assessed using the ROBINS I tool. The meta-analysis was performed using Review Manager software with a random effect model.
Six NRS with a total of 1700 patients were included. No significant differences were found when comparing short prolonged antibiotic therapy as defined by the authors for 90-day mortality [odds ratio (OR): 1.09; 95% confidence interval (CI): 0.82-1.46, : 0.55; = 0%] or 90-day recurrence or relapse of bacteremia [OR: 0.72; 95% CI: 0.31-1.68, : 0.45; = 26%]. Sensitivity analysis showed similar results when comparing a predefined duration of <14 days ⩾14 days and when excluding the only study with a high risk of bias.
Shorter-duration regimens could be considered as an alternative option for uncomplicated SAB in low-risk cases. However, based on a small number of studies with significant methodological limitations and risk of bias, the benefits and harms of shorter regimens should be analyzed with caution. Randomized clinical trials are needed to determine the best approach regarding the optimal duration of therapy.
单纯性菌血症仍然是住院患者发病和死亡的主要原因。当前指南建议至少治疗14天。
评估短期常规抗生素治疗对成人单纯性菌血症(SAB)的疗效和安全性。
我们制定了一项检索策略,以识别截至2023年6月在MEDLINE、Embase和Cochrane注册库中比较短期常规或长期抗生素方案治疗单纯性SAB的非随机研究(NRS)的系统评价和荟萃分析。使用ROBINS I工具评估偏倚风险。使用具有随机效应模型的Review Manager软件进行荟萃分析。
纳入了6项NRS,共1700例患者。在比较作者定义的短期与长期抗生素治疗的90天死亡率[比值比(OR):1.09;95%置信区间(CI):0.82 - 1.46,I² = 0%]或菌血症的90天复发或再发率[OR:0.72;95% CI:0.31 - 1.68,I² = 26%]时,未发现显著差异。敏感性分析显示,在比较预定义的<14天与≥14天疗程时以及排除唯一一项具有高偏倚风险的研究时,结果相似。
对于低风险病例的单纯性SAB,较短疗程方案可被视为一种替代选择。然而,基于少数存在显著方法学局限性和偏倚风险的研究,应谨慎分析较短疗程方案的利弊。需要进行随机临床试验以确定关于最佳治疗持续时间的最佳方法。